SAB Biotherapeutics establishes new $75M ATM equity program via UBS, terminates prior $20M ATM

SAB Biotherapeutics, Inc.

Entered sales agreement with UBS Securities for at-the-market offering of common stock up to $75 million aggregate offering price.
Prior $20M ATM program with Cantor Fitzgerald terminated effective Dec 17, 2025; Cantor waived 60-day restriction.
Net proceeds intended for pipeline development, general corporate and working capital purposes.
Agent fee up to 3% of gross proceeds; program may be terminated by either party on 10 days' notice.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.